Background: Asthma is a chronic inflammatory disease with structural changes present. Burgess and colleagues recently found tumstatin markedly reduced in adult asthmatic lung tissue compared with nonasthmatics. ECM fragments such as tumstatin are named matrikines and act independently of the parent molecule. The role of Col IV matrikines in neutrophil inflammation (eg. exacerbation in asthma) has not been investigated to date. Severe adult asthma phenotypes are dominated by neutrophilic inflammation and show a high frequency of severe exacerbations.
Objective: This study sought to investigate the role of a novel active region within tumstatin (CP17) and its implication in neutrophil inflammatory responses related to asthma exacerbation.
Methods: For reactive oxygen production, isolated neutrophils were preincubated with peptides or vehicle for 1 hour and stimulated (PMA). Luminescence signal was recorded (integration over 10 seconds) for 1.5 hours. Neutrophil migration was performed according to the SiMA protocol. Mice were sensitized to OVA/Alumn by intraperitoneal (i.p.) injections. Mice were then treated with CP17, vehicle (PBS) or scrambled peptide (SP17) after OVA exposure (days 27 and 28, polyI:C stimulation). All animals were killed on day 29 with lung function measurement, histology and lavage.
Results: CP17 decreased total ROS production rate to 52.44% (0.5 μmol/L, P < 0.05 vs SP17), reduced the in vitro directionality (vs SP17, P = 1 × 10 ) and migration speed (5 μmol/L, P = 1 × 10 ). In vivo application of CP17 decreased neutrophil inflammation ~1.8-fold (P < 0.001 vs SP17) and reduced numbers of mucus-producing cells (-29%, P < 0.05).
Conclusion: CP17 reduced the ROS production rate, migrational speed and selectively inhibited neutrophil accumulation in the lung interstitium and lumen.
Clinical Relevance: CP17 may serve as a potential precursor for drug development to combat overwhelming neutrophil inflammation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cea.13236 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Regulatory Mechanism of CXCL16 Molecule-Related Antigen Presentation Using lncRNA-mRNA Co-Expression Network Analysis.
J Inflamm Res
December 2024
Beijing Institute of Heart, Lung and Blood Vessel Diseases, The Key Laboratory of Remodeling Cardiovascular Diseases, Ministry of Education, Collaborative Innovation Center for Cardiovascular Disorders, Beijing Anzhen Hospital, Capital Medical University, Beijing, People's Republic of China.
Aim: To investigate the regulatory mechanism of CXCL16 molecule-related ( extract-induced antigen presentation in a mouse asthma model based on the long non-coding RNA (lncRNA) and mRNA expression profile.
Methods: knockout mice and wild-type mice were administered with . extract by intratracheal instillations to induce asthma airway inflammation.
Transient Receptor Potential Ankyrin 1 (TRPA1) Mediated LPS-Induced Inflammation in Periodontal Ligament Stem Cells by Inhibiting the Phosphorylation of JNK.
Stem Cells Int
December 2024
State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Orthodontics, School of Stomatology, The Fourth Military Medical University, No. 169 Changle West Road, Xi'an 710032, China.
Transient receptor potential ankyrin 1 (TRPA1) molecule is an important type of transient receptor potential (TRP) cation channels, which can cause extracellular Ca to flow into cells after activation. TRPA1 plays an important role in acute and chronic pain, inflammation, kidney disease, cough and asthma, osteoarthritis, cardiovascular disease, obesity, diabetes, and other diseases. In this study, the expression of interleukin (IL)-1, IL-6, and IL-8 in periodontal ligament stem cells (PDLSCs) treated by lipopolysaccharide (LPS) and the effect of LPS on PDLSCS proliferation were detected.
View Article and Find Full Text PDFHodgkin Lymphoma As the Underlying Cause of a Chronic Cough.
Cureus
November 2024
Family Medicine, UCSP Paço de Arcos, Unidade Local de Saúde Lisboa Ocidental, Lisbon, PRT.
Hodgkin lymphoma (HL) is a monoclonal lymphoid neoplasm derived from B cells and is one of the most common lymphomas among young adults in developed countries. It typically presents insidiously, often as a painless cervical lymphadenopathy or an asymptomatic mediastinal mass. B symptoms (fever, night sweats, and weight loss), fatigue, pruritus, or alcohol-induced pain may be present along with respiratory symptoms in cases of mediastinal involvement.
View Article and Find Full Text PDFTracheobronchopathia osteochondroplastica as an unusual cause of chronic cough.
Med J Armed Forces India
December 2024
Classified Specialist (Pathology & Oncopathology), Armed Forces Medical College, Pune, India.
A cough that persists for more than 8 weeks is defined as a chronic cough. In routine practice, asthma, gastroesophageal reflux disease, and postnasal drip are the most common causes of chronic cough. A 58-year-old non-smoking male patient with no known comorbidities presented with a 3-month history of non-productive cough.
View Article and Find Full Text PDFEarly and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study.
J Asthma Allergy
December 2024
Pulmonology Clinic, Cantonal Hospital Graubünden, Chur, Switzerland.
Purpose: Although studies have evaluated benralizumab, a monoclonal IL-5 receptor α antibody in severe eosinophilic asthma (SEA), in real-world settings, additional evidence is needed to further characterize its effectiveness in specific patient populations. Our study aimed to evaluate asthma control over 56 weeks in patients treated with benralizumab in Swiss real-world settings.
Patients And Methods: Conducted across 13 centres, this prospective, observational, non-interventional study involved 73 adults with physician confirmed SEA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!